James Best - Selected Publications#

1. Furler, J., O'Neal, D., Speight, J., Blackberry, I., Manski-Nankervis, J.A., Thuraisingam, S., de La Rue, K., Ginnivan, L., Doyle, R., Holmes-Truscott, E., Khunti, K., Dalziel, K., Chiang, J., Audehm, R., Kennedy, M., Clark, M., Jenkins, A., Lake, A.J., Januszewski, A.S,, Catchpool, M., Liew, D., Clarke, P., Best, J. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes Endocrinol. 8(1):17-26. doi: 10.1016/S2213-8587(19)30385-7, 2020.

One of 18 publications on management of type 2 diabetes in the primary care setting in Australia. The research program was initiated within a national grant led by JB resulting in significant career development of several general practice based clinicians.

2. Boyle, D.I.R., Versace, V.L., Dunbar, J.A., Scheil, W., Janus, E., Oats, J.J.N., Skinner, T., Shih, S., O’Reilly, S., Sikaris, K., Kelsall, L., Phillips, P., A., Best, J., D., on behalf of MAGDA Study Group. Results of the first recorded evaluation of a national gestational diabetes register: Challenges in screening, registration, and follow-up for diabetes risk. PLoS ONE 13: e0200832, 2018.

One of eight papers evaluating a population based study of diabetes prevention in women at risk because of gestational diabetes. JB was a senior investigator on the whole project and chaired the implementation committee. He provided expertise on multiple aspects of the study, including data analysis and interpretation.

3. Best, J.D., Drury, P.L., Davis, T.M.E., Taskinen, M.R., Kesäniemi, Y.A., Scott, R., Pardy, C., Voysey, M., Keech, A.C.; on behalf of the FIELD study investigators. Glycemic control over 5 years in 4900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care. 35: 1165-1170, 2012.

This paper is representative of 11 publications from the FIELD study. At the time it was the largest clinical study ever completed in type 2 diabetes, involving 9,795 people from Australia, New Zealand and Finland. The results provide an evidence base for the use of the drug fenofibrate in type 2 diabetes; evidence was lacking despite widespread use of the drug for over 20 years in the management of dyslipidaemia. JB played a major role as a member of the Management Committee Executive.

4. Vale, M.J., Jelinek, M.V., Best, J.D. Impact of coaching patients on coronary risk factors. Lessons from the COACH program. Dis. Manage. Health Outcomes 13:1-21, 2005

A novel approach to managing cardiovascular risk factors for secondary prevention of coronary heart disease and its extension to diabetes management led to nine publications. The specific coaching technique was adopted across Australia and also in the Netherlands and the UK. The 2018 publication International Cardiovascular Disease Prevention case studies by the British Heart Foundation and Public Health England states on page 26: When assessing the published literature for the case studies COACH had more evidence based publications outlining the benefits to patients and the health economy than any of the

other programmes.

5. Macheda, M.L., Rogers, S., Best, J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202: 654-662, 2005.

One of 14 publications on GLUT proteins and their expression in a range of tissues, including foetal tissue, breast and prostate cancers. This review has been cited almost 1,000 times.

6. Rogers, S., Macheda, M.L., Docherty, S.E., Henderson, M.A., James, D.E., Best, J.D. Identification of a novel glucose transporter like protein – GLUT12. Am. J. Physiol. Endocrinol. Metab. 282: E733-E738, 2002.

The discovery of a novel GLUT protein in breast cancer cells highlighted the potential role of GLUTS in metabolism of cancer cells. It has subsequently been found in other cancers, with many other publications by other authors on its location and regulation.

7. Best, J.D., Kahn, S.E., Ader, M., Watanabe, R.M., Ni, T-C., Bergman, R.N. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care. 19:1018-1030, 1996.

Review paper on the concept of glucose induced glucose disposal. One of 15 papers on the physiology of glucose metabolism that included measurement of this factor in glucose disposal from the circulation.

8. Jenkins, A.J., Steele, J.S., Janus, E.D., Best, J.D. Increased apolipoprotein (a) levels in IDDM patients with microalbuminuria. Diabetes 40:787-790, 1991.

One of over 50 publications on lipid metabolism in a variety of disorders, including type 1 and type 2 diabetes, renal disease and rheumatoid arthritis.

9. Leonard, D., McDermott, R., O’Dea, K., Rowley, K., Pensio, P., Sambo, E., Twist, A., Toolis, R., Lowson, S., Best, J. High prevalence of obesity, diabetes and associated cardiovascular risk factors among indigenous people of the Torres Strait and Northern Peninsula Area. Aust. N.Z. J. Public Health 26: 144-149, 2002.

The Australian Indigenous peoples have a high rate of diabetes, cardiovascular disease and renal disease. This is one of 30 publications from community based studies, documenting the basis of this higher risk, including nutritional factors, anti-oxidant levels and lipid abnormalities.

10. Best, J.D., Taborsky Jr, G.J., Halter, J.B., Porte Jr, D. Glucose disposal is not proportional to plasma glucose level in man. Diabetes 30:847-850, 1981.

An early publication that challenged conventional belief at the time and led to ingoing studies on glucose metabolism and glucose transporter proteins.